Research and treatment timeline: 30+ years of ms milestones | 4
Research and treatment timeline: 30+ years of ms milestones | 4
Research and treatment timeline: 30+ years of ms milestones | 4
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
special feature: Spotlight on research<br />
Whether discovering new ways to treat sympto<strong>ms</strong> or trying to find a cure, researchers<br />
are working hard to make advances that will benefit the lives <strong>of</strong> people with MS. Through<br />
research in the areas <strong>of</strong> myelin repair, symptom management, environment as a possible<br />
cause <strong>and</strong> the development <strong>of</strong> <strong>treatment</strong>s for MS, the research <strong>of</strong> today looks to form a<br />
path to a brighter future for those who live with MS.<br />
In this special feature, we are pleased to highlight some <strong>of</strong> the important research<br />
happening right now in the MS community.<br />
myelin repair<br />
Myelin is<br />
the fatty<br />
coating that<br />
protects <strong>and</strong><br />
surrounds nerve<br />
fibres within the<br />
central nervous<br />
system. Often<br />
compared to the<br />
insulating material around electrical<br />
wiring, myelin aids the conduction <strong>of</strong><br />
electrical signals between neurons<br />
within the spinal cord <strong>and</strong> brain.<br />
Multiple sclerosis involves the body’s<br />
immune system attacking <strong>and</strong><br />
destroying myelin. Such demyelination<br />
can cause interference in transmitting<br />
nerve signals, which can cause blurred<br />
vision, slurred speech, trembling <strong>and</strong><br />
cognitive difficulties.<br />
Some approved therapies for MS<br />
involve slowing down the body’s<br />
immune system to prevent it<br />
from attacking the myelin. Such<br />
<strong>treatment</strong> can prevent the disease<br />
from progressing <strong>and</strong> can minimize<br />
attacks. <strong>Research</strong> is currently<br />
ongoing with regard to developing<br />
techniques to induce myelin repair<br />
with antibodies; however, studies<br />
are still exploring if this method can<br />
be effective in restoring the loss <strong>of</strong><br />
myelin in humans.<br />
What’s happening now<br />
Michael Keough<br />
university <strong>of</strong> Calgary<br />
PhD studentship<br />
Michael Keough is the recipient<br />
<strong>of</strong> a 2012 MS Society <strong>of</strong><br />
Canada Doctoral Award for his<br />
project, “Altering the Inhibitory<br />
Microenvironment to Promote<br />
Oligodendrocyte Maturation <strong>and</strong> Remyelination.”<br />
Remyelination is characteristic in acute multiple<br />
sclerosis (MS) lesions yet <strong>of</strong>ten fails in chronic<br />
stages <strong>of</strong> disease. Oligodendrocyte precursor cells<br />
(OPCs) reside in chronic MS lesions in immature<br />
states, suggesting that inhibitory molecules in the<br />
lesion environment cause remyelination failure.<br />
Extracellular matrix molecules called “chondroitin<br />
sulfate proteoglycans” are abnormally elevated in<br />
chronic MS lesions, <strong>and</strong> data indicates that they are<br />
responsible for remyelination failure.<br />
Mr. Keough’s goal is to further analyze these<br />
molecules <strong>and</strong> seek therapeutics to overcome<br />
their inhibition <strong>of</strong> OPCs, such that remyelination<br />
can be possible in chronic stages <strong>of</strong> MS.<br />
“There are currently no MS medications targeted to<br />
directly impact regeneration <strong>of</strong> lost myelin,” Keough<br />
says. “A new angle <strong>of</strong> <strong>treatment</strong>, in combination with<br />
current <strong>and</strong> advancing immunomodulatory therapies,<br />
may be beneficial to people living with MS.”<br />
<strong>ms</strong> canada Fall/Winter 2012 5